Tuberculosis and HIV co-infection, California, USA, 1993-2008

Emerging Infectious Diseases

Volumn 19, Issue 3, 2013, Pages 400-406

  Metcalfe, John Z ^a   Porco, Travis C ^a   Westenhouse, Janice ^b   Damesyn, Mark ^c   Facer, Matt ^c   Hill, Julia ^b   Xia, Qiang ^d   Watt, James P ^b   Hopewell, Philip C ^a   Flood, Jennifer ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^c CALIFORNIA DEPARTMENT OF PUBLIC HEALTH   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE CONTROL; DISEASE TRANSMISSION; ETHNIC AND RACIAL GROUPS; FEMALE; HIGH RISK POPULATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMIGRANT; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; RETROSPECTIVE STUDY; TUBERCULOSIS; UNITED STATES;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CALIFORNIA; COINFECTION; EPIDEMIOLOGICAL MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 84874271037     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1903.121521     Document Type: Article

References (40)

1. Centers for Disease Control and Prevention. Trends in tuberculosis-United States, 2011. MMWR Morb Mortal Wkly Rep. 2012;61:181-5.
2. World Health Organization. Global tuberculosis report 2012 [cited 2012 Nov 28]. http://www.who.int/tb/publications/global_report/en
3. Getahun H, Gunneberg C, Granich R, Nunn P. HIV infection-associated tuberculosis: the epidemiology and the response. Clin Infect Dis. 2010;50(Suppl 3):S201-7. http://dx.doi.org/10.1086/651492
4. Wong EB, Omar T, Setlhako GJ, Osih R, Feldman C, Murdoch DM, et al. Causes of death on antiretroviral therapy: a post-mortem study from South Africa. PLoS ONE. 2012;7:e47542. http://dx.doi.org/10.1371/journal.pone.0047542
5. Centers for Disease Control and Prevention. Diagnoses of HIV infection and AIDS in the United States and dependent areas, 2009 [cited 2012 Jun 13]. http://www.cdc.gov/hiv/surveillance/resources/reports/2009report/index.htm
6. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr. 2009;51(Suppl 1):S13-20. http://dx.doi.org/10.1097/QAI.0b013e3181a2639e
7. Centers for Disease Control and Prevention. Mortality among patients with tuberculosis and associations with HIV status-United States, 1993-2008. MMWR Morb Mortal Wkly Rep. 2010;59:1509-13.
8. Bacchetti P, Segal MR, Jewell NP. Backcalculation of HIV infection rates. Stat Sci. 1993;8:82-119. http://dx.doi.org/10.1214/ss/1177010994
9. Sprinson JE, Lawton ES, Porco TC, Flood JM, Westenhouse JL. Assessing the validity of tuberculosis surveillance data in California. BMC Public Health. 2006;6:217. http://dx.doi.org/10.1186/1471-2458-6-217
10. Klevens RM, Fleming PL, Li J, Gaines CG, Gallagher K, Schwarcz S, et al. The completeness, validity, and timeliness of AIDS surveillance data. Ann Epidemiol. 2001;11:443-9. http://dx.doi.org/10.1016/S1047-2797(01)00256-3
11. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States. MMWR Recomm Rep. 2008;57(RR-10):1-12.
12. State of California, Department of Finance. Race/ethnic population with age and sex detail, 1990-1999 and 2000-2050 [cited 2012 Jan 1]. http://www.dof.ca.gov/research/demographic/reports/estimates/e-1/view.php
13. Thompson ML, Myers JE, Kriebel D. Prevalence odds ratio or prevalence ratio in the analysis of cross sectional data: what is to be done? Occup Environ Med. 1998;55:272-7. http://dx.doi.org/10.1136/oem.55.4.272
14. Lindquist K. UCLA Institute for Digital Research and Education [cited 2012 Jun 1]. http://www.ats.ucla.edu/stat/stata/faq/relative_risk.htm
15. Rubin DB. Multiple imputation for nonresponse in surveys. New York: Wiley; 1987.
16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359:2059-64. http://dx.doi.org/10.1016/S0140-6736(02)08904-3
17. Dembélé M, Saleri N, Carvalho AC, Saouadogo T, Hien AD, Zabsonre I, et al. Incidence of tuberculosis after HAART initiation in a cohort of HIV-positive patients in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:318-23.
18. Centers for Disease Control and Prevention. Expanded tuberculosis surveillance and tuberculosis morbidity-United States, 1993. MMWR Morb Mortal Wkly Rep. 1994;43:361-6.
19. Chaulk CP, Moore-Rice K, Rizzo R, Chaisson RE. Eleven years of community-based directly observed therapy for tuberculosis. JAMA. 1995;274:945-51. http://dx.doi.org/10.1001/jama.1995.03530120037038
20. Pimpin L, Drumright LN, Kruijshaar ME, Abubakar I, Rice B, Delpech V, et al. Tuberculosis and HIV co-infection in European Union and European economic area countries. Eur Respi J. 2011;38:1382-92. http://dx.doi.org/10.1183/09031936.00198410
21. Staehelin C, Rickenbach M, Low N, Egger M, Ledergerber B, Hirschel B, et al. Migrants from sub-Saharan Africa in the Swiss HIV Cohort Study: access to antiretroviral therapy, disease progression and survival. AIDS. 2003;17:2237-44. http://dx.doi.org/10.1097/00002030-200310170-00012
22. Albalak R, O'Brien RJ, Kammerer JS, O'Brien SM, Marks SM, Castro KG, et al. Trends in tuberculosis/human immunodeficiency virus comorbidity, United States, 1993-2004. Arch Intern Med. 2007;167:2443-52. http://dx.doi.org/10.1001/archinte.167.22.2443
23. Espinoza L, Hall HI, Hu X. Increases in HIV diagnoses at the U.S.-Mexico border, 2003-2006. AIDS Educ Prev. 2009;21(Suppl):19-33. http://dx.doi.org/10.1521/aeap.2009.21.5_supp.19
24. Hlavsa MC, Moonan PK, Cowan LS, Navin TR, Kammerer JS, Morlock GP, et al. Human tuberculosis due to Mycobacterium bovis in the United States, 1995-2005. Clin Infect Dis. 2008;47:168-75. http://dx.doi.org/10.1086/589240
25. Chang KC, Yew WW, Zhang Y. Pyrazinamide susceptibility testing in Mycobacterium tuberculosis: a systematic review with meta-analyses. Antimicrob Agents Chemother. 2011;55:4499-505. http://dx.doi.org/10.1128/AAC.00630-11
26. Hall HI, Song R, Rhodes P, Prejean J, An Q, Lee LM, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520-9. http://dx.doi.org/10.1001/jama.300.5.520
27. Centers for Disease Control and Prevention. Reported HIV status of tuberculosis patients-United States, 1993-2005. MMWR Morb Mortal Wkly Rep. 2007;56:1103-6.
28. Rodwell TC, Barnes RF, Moore M, Strathdee SA, Raich A, Moser KS, et al. HIV-tuberculosis coinfection in southern California: evaluating disparities in disease burden. Am J Public Health. 2010;100(Suppl 1):S178-85. http://dx.doi.org/10.2105/AJPH.2009.170142
29. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS. 2006;20:1605-12. http://dx.doi.org/10.1097/01.aids.0000238406.93249.cd
30. Friedman LN, Williams MT, Singh TP, Frieden TR. Tuberculosis, AIDS, and death among substance abusers on welfare in New York City. N Engl J Med. 1996;334:828-33. http://dx.doi.org/10.1056/NEJM199603283341304
31. Chamie G, Luetkemeyer A, Walusimbi-Nanteza M, Okwera A, Whalen CC, Mugerwa RD, et al. Significant variation in presentation of pulmonary tuberculosis across a high resolution of CD4 strata. Int J Tuberc Lung Dis. 2010;14:1295-302.
32. Cain KP, Anekthananon T, Burapat C, Akksilp S, Mankhatitham W, Srinak C, et al. Causes of death in HIV-infected persons who have tuberculosis, Thailand. Emerg Infect Dis. 2009;15:258-64. http://dx.doi.org/10.3201/eid1502.080942
33. Behr MA, Warren SA, Salamon H, Hopewell PC, Ponce de Leon A, Daley CL, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999;353:444-9. http://dx.doi.org/10.1016/S0140-6736(98)03406-0
34. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr. 2009;51:399-406. http://dx.doi.org/10.1097/QAI.0b013e3181acb4e5
35. Centers for Disease Control and Prevention. Vital signs: HIV testing and diagnosis among adults-United States, 2001-2009. MMWR Morb Mortal Wkly Rep. 2010;59:1550-5.
36. Xia Q, Westenhouse JL, Schultz AF, Nonoyama A, Elms W, Wu N, et al. Matching AIDS and tuberculosis registry data to identify AIDS/tuberculosis comorbidity cases in California. Health Informatics J. 2011;17 [cited 2012 Dec 11]. http://jhi.sagepub.com/content/17/1/41
37. Kong DWJ, Marks S, Flood J. HIV status determination among tuberculosis patients from California in 2008. J Public Health Manag Pract. 2012. In press.
38. Horsburgh CR Jr, Rubin EJ. Clinical practice. Latent tuberculosis infection in the United States. N Engl J Med. 2011;364:1441-8. http://dx.doi.org/10.1056/NEJMcp1005750
39. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med. 2011;365:2155-66. http://dx.doi.org/10.1056/NEJMoa1104875
40. California Assembly Bill No. 2541, Ch. 470. Approved and filed on 2010 Sep 29 [cited 2011 Dec 1]. http://www.leginfo.ca.gov/pub/09-10/bill/asm/ab_2501-2550/ab_2541_bill_20100929_chaptered.pdf